EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies

Teresa Alonso-Gordoa, Georgia Anguera, Mario Domínguez-Esteban, Òscar Reig, Hilario Martínez-Barros, Javier Molina-Cerrillo, Patricia Cruz, Pablo Maroto

Cancer Treatment Reviews · 2025

DOI: 10.1016/j.ctrv.2025.102925 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025. Verfasst von Teresa Alonso-Gordoa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: jmaroto@santpau.cat. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has changed the management of localized clear cell renal cell carcinoma (ccRCC) since the approval of adjuvant pembrolizumab, which demonstrated significant improvements in disease-free survival (DFS) and overall survival (OS) in patients at intermediate and high risk of recurrence. This new approach impacts rescue strategies in patients who relapse after local treatment and during or after adjuvant pembrolizumab. Nevertheless, there is currently no robust scientific evidence on therapeutic decision-making in this clinical situation, representing an area for further debate and research. In this article, a group of experts from the Genitourinary Alliance for Research and Development (GUARD) have reviewed the available scientific evidence to establish the basis for therapeutic decision-making in patients with ccRCC who progress after adjuvant treatment with immunotherapy. Despite the lack of randomized clinical trials in this setting, this group of experts recommends classifying patients according to relapse volume (oligometastatic vs. polymetastatic), time to relapse and certain molecular characteristics. Rescue treatments beyond relapse should be individualized and might include locoregional treatments such as surgery or radiotherapy as well as antiangiogenic therapies in patients defined as resistant to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellImmunotherapyHumansDisease ProgressionConsensusChemotherapy, AdjuvantNeoplasm Recurrence, LocalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Adjuvant treatmentClear cell renal cell carcinomaImmunotherapyRecurrenceTreatment strategies

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: jmaroto@santpau.cat.
  • Medical- Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain. Electronic address: ganguera@santpau.cat.
  • Urology Department, IDIVAL, Marqués de Valdecilla University Hospital, Santander, Spain. Electronic address: mariodominguezesteban@gmail.com.
  • Laboratory of Translational Genomics and Targeted Therapies in Solid Tumours, Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Medicine Department, Barcelon…
  • Oncology Pharmacy Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: hilario.martinez.barros@gmail.com.
  • Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: javier.molinace@gmail.com.

Zitieren

APA

Alonso-Gordoa, T., Anguera, G., Domínguez-Esteban, M., Reig, Ò., Martínez-Barros, H., Molina-Cerrillo, J., Cruz, P., & Maroto, P. (2025). Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2025.102925

Vancouver

Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, et al. Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews. 2025. doi:10.1016/j.ctrv.2025.102925

BibTeX
@article{AlonsoGordoa2025,
  author = {Alonso-Gordoa, Teresa and Anguera, Georgia and Domínguez-Esteban, Mario and Reig, Òscar and Martínez-Barros, Hilario and Molina-Cerrillo, Javier and Cruz, Patricia and Maroto, Pablo},
  title = {Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  doi = {10.1016/j.ctrv.2025.102925}
}
Kostenlos starten →